MA44408A - Méthode de traitement de la réaction du greffon contre l'hôte (gvd) - Google Patents

Méthode de traitement de la réaction du greffon contre l'hôte (gvd)

Info

Publication number
MA44408A
MA44408A MA044408A MA44408A MA44408A MA 44408 A MA44408 A MA 44408A MA 044408 A MA044408 A MA 044408A MA 44408 A MA44408 A MA 44408A MA 44408 A MA44408 A MA 44408A
Authority
MA
Morocco
Prior art keywords
gvd
versus host
host reaction
treating graft
graft
Prior art date
Application number
MA044408A
Other languages
English (en)
French (fr)
Inventor
John E Ford
Jessica A Sachs
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MA44408A publication Critical patent/MA44408A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA044408A 2016-03-14 2017-03-13 Méthode de traitement de la réaction du greffon contre l'hôte (gvd) MA44408A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662307896P 2016-03-14 2016-03-14

Publications (1)

Publication Number Publication Date
MA44408A true MA44408A (fr) 2019-01-23

Family

ID=58448610

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044408A MA44408A (fr) 2016-03-14 2017-03-13 Méthode de traitement de la réaction du greffon contre l'hôte (gvd)

Country Status (13)

Country Link
US (1) US20200002422A1 (cg-RX-API-DMAC7.html)
EP (1) EP3430052A2 (cg-RX-API-DMAC7.html)
JP (2) JP2019508448A (cg-RX-API-DMAC7.html)
KR (1) KR102710759B1 (cg-RX-API-DMAC7.html)
CN (2) CN109071660A (cg-RX-API-DMAC7.html)
AU (1) AU2017234009B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018068628A2 (cg-RX-API-DMAC7.html)
CA (1) CA3017743A1 (cg-RX-API-DMAC7.html)
EA (1) EA201892071A1 (cg-RX-API-DMAC7.html)
IL (1) IL261750B2 (cg-RX-API-DMAC7.html)
MA (1) MA44408A (cg-RX-API-DMAC7.html)
MX (2) MX2018011169A (cg-RX-API-DMAC7.html)
WO (1) WO2017160699A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019512493A (ja) * 2016-03-14 2019-05-16 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 移植片対宿主病の処置または予防の方法
JP7202893B2 (ja) 2016-06-12 2023-01-12 武田薬品工業株式会社 炎症性腸疾患を治療する方法
CN111971052B (zh) * 2018-02-08 2024-07-05 小利兰.斯坦福大学托管委员会 用于异基因造血干细胞移植的方法
WO2021222239A1 (en) * 2020-04-27 2021-11-04 Children's Hospital Medical Center Precision dosing regimen
AU2024282654A1 (en) 2023-05-30 2025-12-04 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
EP0808367B1 (en) 1995-02-10 2007-07-11 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins and uses thereof
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US20010046496A1 (en) 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
EP2402309A1 (en) 2002-05-24 2012-01-04 Millennium Pharmaceuticals, Inc. CCR9 inhibitors and methods of use thereof
CN101077867B (zh) 2002-11-18 2012-10-10 坎莫森特里克斯公司 芳基磺酰胺
MX350383B (es) 2004-01-09 2017-09-04 Pfizer Anticuerpos contra madcam.
PT1784426E (pt) 2004-09-03 2012-03-06 Genentech Inc Antagonistas humanizados anti-beta7 e suas utilizações
ES2516690T5 (es) * 2005-06-07 2017-11-21 The Regents Of The University Of Colorado, A Body Corporate Inhibidores de la actividad de serina proteasa y su uso en métodos y composiciones para el tratamiento de rechazo de injertos y promoción de supervivencia de injertos
US20070122404A1 (en) 2005-11-17 2007-05-31 O'keefe Theresa L Humanized immunoglobulin reactive with alpha4beta7 integrin
AU2009313039B2 (en) * 2008-11-07 2015-06-18 Amgen Research (Munich) Gmbh Treatment of pediatric acute lymphoblastic leukemia
MX338969B (es) * 2009-03-20 2016-05-06 Amgen Inc Anticuerpo de antagonista especifico de heterodimero alfa-4-beta-7.
CN103260627A (zh) * 2010-11-12 2013-08-21 真蒂奥姆有限公司 去纤维蛋白多核苷酸用于预防和/或治疗移植物抗宿主病(gvhd)
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
ES2646717T3 (es) * 2011-05-02 2017-12-15 Millennium Pharmaceuticals, Inc. Formulación para anticuerpo anti- 4 7
MX370199B (es) * 2012-02-16 2019-12-05 Santarus Inc Composiciones farmaceuticas de anticuerpo anti-antigeno muy tardio (cd49a).
NZ622452A (en) * 2012-06-21 2017-10-27 Compugen Ltd Lsr antibodies, and uses thereof for treatment of cancer
BR112017003546A2 (pt) * 2014-08-21 2017-12-05 Glaxosmithkline Ip Dev Ltd amidas heterocíclicas como inibidores de rip1 quinase como medicamentos
MA41636A (fr) * 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
JP2019512493A (ja) * 2016-03-14 2019-05-16 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 移植片対宿主病の処置または予防の方法

Also Published As

Publication number Publication date
EP3430052A2 (en) 2019-01-23
AU2017234009A1 (en) 2018-09-27
IL261750B2 (en) 2024-07-01
MX2025001934A (es) 2025-04-02
IL261750A (en) 2018-10-31
US20200002422A1 (en) 2020-01-02
MX2018011169A (es) 2018-12-06
IL261750B1 (en) 2024-03-01
KR102710759B1 (ko) 2024-09-25
CN109071660A (zh) 2018-12-21
JP2019508448A (ja) 2019-03-28
WO2017160699A2 (en) 2017-09-21
JP2022163078A (ja) 2022-10-25
EA201892071A1 (ru) 2019-03-29
AU2017234009B2 (en) 2024-06-06
CA3017743A1 (en) 2017-09-21
BR112018068628A2 (pt) 2019-07-30
KR20180120706A (ko) 2018-11-06
WO2017160699A3 (en) 2017-11-23
CN116327920A (zh) 2023-06-27

Similar Documents

Publication Publication Date Title
MA52371A (fr) Méthodes de traitement d'infections dues aux coronaviridae
EP3538130A4 (en) IMMUNOTHERAPEUTIC TUMOR TREATMENT PROCEDURE
EP3380121A4 (en) METHOD FOR THE TREATMENT OF EYE DISEASES
EP3423488A4 (en) METHOD FOR THE TREATMENT OF CANCER
EP3341080A4 (en) METHOD FOR THE TREATMENT OF CANCER
EP3256439A4 (en) Process for production of acrylic acid
DK3204015T3 (da) Forbindelser og fremgangsmåder til inhibition af hao1-genekspression (hydroxysyre oxidase 1 (glycolat oxidase))
MA44408A (fr) Méthode de traitement de la réaction du greffon contre l'hôte (gvd)
EP3440107A4 (en) METHOD FOR TREATING ATHEROSCLEROSIS
EP3455188C0 (de) Verfahren zur behandlung von schlacke
EP3405203A4 (en) METHOD FOR THE TREATMENT OF CANCER
EP3389634A4 (en) METHOD FOR THE TREATMENT OF CANCER
EP3530664A4 (en) DIOL, PROCESS FOR PREPARING DIOL, DI (METH) ACRYLATE AND METHOD FOR PRODUCING DI (METH) ACRYLATE
EP3375440A4 (en) METHOD FOR THE TREATMENT OF MUCOSITIS
EP3440112A4 (en) METHOD FOR THE TREATMENT OF CANCER
GB2551964B (en) Method of treating biomass to remove RNA
EP3703707A4 (en) METHOD FOR TREATMENT OF ACID-BASE DISORDER
EP3448365A4 (en) METHOD FOR TREATING CONSTRUCTION
EP3389652A4 (en) METHOD FOR THE TREATMENT OF CANCER
FR3034011B1 (fr) Procede de traitement cosmetique des cheveux
MA41462A (fr) Méthode de traitement de maladies
PL3544941T3 (pl) Całościowy sposób oczyszczania odpadów biologicznych
IL265696A (en) Methods for treating female infertility
PL3564250T3 (pl) Sposób oczyszczania alulozowego produktu reakcji konwersji
SI3535257T1 (sl) Proces za čiščenje prirazolpiridazinov